Picture EBD Group BioTech Showcase 2021 Digital Event BTS2021 651x81
Document › Details

Cell and Gene Therapy Catapult, The. (9/11/18). "Press Release: Stevenage Cell and Gene Therapy Catapult Centre Gets Green Light to Make New Cell and Gene Therapies".

Region Region Stevenage, Hertfordshire
  Country United Kingdom (GB)
Organisations Organisation Cell and Gene Therapy Catapult Manufacturing Centre in Stevenage
  Group United Kingdom (GB) (govt)
  Organisation 2 MHRA (Medicines and Healthcare Products Regulatory Agency, GB)
Products Product gene therapy
  Product 2 contract manufacturing (biologicals)
Index terms Index term Cell Medica–United Kingdom (govt): cell therapy manfucturing, 201809 supply existent Cell Medica uses CGT Catapult manufacturing centre in Stevenage
  Index term 2 Freeline Therapeutics–United Kingdom (govt): gene therapy manfucturing, 201809 supply Freeline uses CGT Catapult manufacturing centre in Stevenage
Persons Person Thompson, Keith (United Kingdom (govt) 201204– CEO of Cell Therapy Catapult before SNBTS)
  Person 2 Henley, Lord (United Kingdom (govt) 201809 Life Sciences Minister)

New life-changing cell and gene therapies for use in health services around the world will be produced in Stevenage by innovative biotech firms as the Cell and Gene Therapy Catapult (CGT Catapult) is granted new licences.

The licences, awarded by the Medicines and Healthcare products Regulatory Agency (MHRA), will help these companies collaborating with the CGT Catapult at the Stevenage manufacturing centre develop therapies that can progress faster to clinical trials and commercial supply. More cell and gene therapies are becoming available for patients, and the new licences represent a significant step towards establishing the CGT Catapult’s manufacturing centre in Stevenage as a world-leading hub for the production of advanced therapies. The manufacturing centre, opened in April 2018, provides the rapidly growing global cell and gene therapy industry with best-in-class infrastructure to help collaborators develop and commercialise medicines at the cutting edge of medical science.

“The granting of these licences marks an important milestone for the CGT Catapult. It demonstrates how our Stevenage manufacturing centre is becoming one of the world’s leading facilities for the development and production of cell and gene therapies.

The award of these licences in such a short timeframe is testament to the close engagement we have maintained with the MHRA over the past few years for the building of a facility that allows for this unique collaborator model, and one which we will continue to foster as the manufacturing centre and its surrounding innovation cluster grows. We now look forward to working with our current collaborators as they leverage our licences to move towards production of the first batches of clinical materials”.

Keith Thompson, CEO, Cell and Gene Therapy Catapult

The licences have been awarded following inspection by MHRA and are the result of close engagement with MHRA during the design, build and qualification of this unique facility. The centre employs a new manufacturing model to assist collaborating companies to manufacture their innovative cell and gene therapies supported by CGT Catapult.

The centre’s unique operating model allows collaborator companies to manufacture their therapies at scale, all to Good Manufacturing Practice (GMP) standards and underpinned by end-to-end expertise and practical support from CGT Catapult experts across scientific research, manufacturing, supply and regulation.

“The go-ahead to make cell and gene therapies that could ultimately save lives is a great boost for the area, but also shines a light on the whole of the UK as an attractive place for this innovative industry to thrive.

This project supports the ambition of our modern Industrial Strategy to maintain the UK’s standing as a world leader in research and innovation.”

Lord Henley, Life Sciences Minister

The two licences are a Manufacturing and Importation Authorisation (MIA) and an MIA for investigational medicinal product (MIA IMP). These licences are an EU requirement for the production of commercial medicines for patient use or to support clinical trials.

Current companies developing their manufacturing and supply systems at the Centre include Autolus, Cell Medica, Adaptimmune and Freeline and the centre is already being expanded to meet demand.

Record changed: 2018-09-14


Picture Kentro Design Corporate and Web Design Berlin 650x65px

More documents for United Kingdom (GB) (govt)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture EBD Group Digital Medicine & Medtech Showcase 2021 at BTS2021 651x81

» top